Blood
Articles in this Issue
Large language models extract diverse manifestations of chronic GVHD from unstructured clinical documentation
Abstract Background Chronic graft-versus-host disease (cGVHD) is a pleomorphic clinical entity that causes significant morbidity and mortali...
Variability in interventional trials in clonal haematopoiesis
Abstract Background Clonal haematopoiesis (CH) is an important cause of age-related diseases, characterised by the clonal outgrowth of hemat...
Platelet priming in MPN triggers pro-thrombotic intermediate affinity state in αIIbβ3 integrin
Abstract Introduction: Myeloproliferative neoplasms (MPN) are associated with both a higher risk of thrombosis and bleeding. Interestingly,...
Comparative safety and effectiveness of direct oral anticoagulants and low-molecular weight heparin in patients with venous thromboembolism and cancer in europe
Abstract Objectives Cancer associated venous thromboembolism (VTE) poses a dual risk of thrombosis and bleeding, making its management parti...
The somatic hotspot mutation of DDX41 (p.R525H) elicits dominant-negative effects upon non-truncating germline variants, explaining similar disease risk as truncating variants.
Abstract Heterozygous germline variants of DDX41 occur in 2-4% of adult Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) case...
Differential impacts of Lama4 deficient microenvironment on fitness of BCR::ABL1-expressing cells during chronic myeloid leukemia initiation and progression
Abstract Introduction: Chronic myeloid leukemia (CML) is a clonal stem cell disease driven by BCR::ABL1 fusion gene. It has been proposed th...
F1 subunit-specific ATP synthase inhibition disrupts AML mitochondrial metabolism distinctly from other electron transport chain inhibitors
Abstract Targeting oxidative phosphorylation (OXPHOS) has long been pursued, but a suitable therapeutic window has been elusive in the devel...
Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study
Abstract Background: Indolent B-cell lymphomas (iBCL), accounting for 10-15% of non-Hodgkin lymphoma (NHL) subtypes in China, exhibit clinic...
Interferon-gamma production in the bone marrow of myelodysplastic syndrome patients supports a treg-independent immune-tolerant microenvironment
Abstract Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological malignancies with an increased risk of evolving into Acu...
Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center
Abstract Background: Equecabtagene autoleucel (eque-cel), a fully human BCMA-targeted CAR-T therapy, has exhibited unprecedented efficacy in...
Evaluating reproductive health service delivery at nascc recognized comprehensive sickle cell centers
Abstract Introduction: Reproductive health services are increasingly recognized as an important dimension of comprehensi...
Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study
Abstract Introduction: Talquetamab (Tal) is the first G protein–coupled receptor class C group 5 member D (GPRC5D) × CD3 bispecific antibody...
Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis
Abstract INTRODUCTION The ECHELON-2 trial for newly diagnosed CD30+ peripheral T-cell lymphomas (PTCL) demonstrated superior overall survival...
Aberrant cell cycle regulation and osteoblastic differentiation in diamond-blackfan anemia (DBA) mesenchymal stem cells
Abstract Diamond-Blackfan anemia (DBA) is a rare hematological disorder characterized by red blood cell aplasia. Advances in genomic studies...
EMU-116: An oral CXCR4 antagonist as mobilizer of stem and immune cells in normal, neutropenic and sickle cell mice.
Abstract The use of CXCR4 antagonists as cell mobilization agents has resulted in 3 FDA approved drugs for use in hematopoietic stem cell tr...
Cd39 overexpression in AML blasts elicits an immune suppressive bone barrow microenvironment via G3/G4 neutrophils and Th1 cells
Abstract Introduction:Cd39 expression in TIB-49 cells enhances the stemness and aggressiveness of AML blasts in vivo (PMID: 39157874, EHA202...
Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center
Abstract Introduction: Chronic myelomonocytic leukemia (CMML) is a rare myeloid neoplasm. The outcomes of patients (pts) with CMML treated w...
Outcomes for low-income patients with multiple myeloma: A national retrospective trend analysis from 2015 to 2022
Abstract Introduction: Despite global decreases in overall cancer incidence, the incidence of multiple myeloma (MM) continues to increase at...
Development of a novel evidence-based diagnostic scoring system for fat embolism in sickle cell disease: The FE-SCD score
Abstract Background: Fat embolism syndrome represents a rare but severe complication in sickle cell disease patients. Unlike fat embolism as...
One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus
Abstract Introduction Systemic lupus erythematosus (SLE) is a complex autoimmune disease driven by abnormal activation o...
Trends in mortality due to lymphoma and pulmonary embolism in the United States, 1999–2020: A CDC wonder database population analysis
Abstract Introduction: Lymphoma is associated with many serious complications one which includes pulmonary embolism (PE). If these occur tog...
Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-world multicenter study
Abstract Background: Relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains a significant therapeuti...
Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China
Abstract Introduction: The landmark POLARIX study showed that Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and...
Genoprime-Perturb-seq: Functional dissection of GATA2 variants via simultaneous Genotyping-coupled Prime-editing Perturb-seq
Abstract The master transcription factor GATA2 is indispensable for hematopoietic stem cell homeostasis and the integrity of multilineage bl...
Oncofetal RNA-binding proteins IGF2BP suppress innate immunity signaling pathways in leukemia stem cells
Abstract Activation of innate inflammatory signaling and tumor-specific antigen presentation in cancerous cells lays a foundation for antica...